Posted on February 14, 2013 by Sitemaster
A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, aflibercept, ARN-509, cabazitaxel, cediranib, dasatinib, enzalutamide, radium-223, sipuleucel-T | 6 Comments »
Posted on March 10, 2011 by Sitemaster
One of the great unanswered questions (so far) is whether adding a tyrosine kinase inhibitor (a TKI) to docetaxel + prednisone can improve outcomes for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, cediranib, mCRPC, metastatic, TKI, tyrosine kinase inhibitor | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 